Clinical Trial Update: A Dose Escalation and Safety Study of Plasmin (Human) In Acute Lower Extremity Native Artery or Bypass Graft Occlusion [Phase 1]

View source ↗

Summary

A Phase 1 dose-escalation and safety study of human plasmin in acute lower-extremity arterial occlusion due to native arteries or bypass grafts has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Arterial Occlusive Disease
• Limb Ischemia

Drugs mentioned

• Plasmin (Human) (plasmin)

Snippet

Sponsor: Grifols Therapeutics LLC | Conditions: Arterial Occlusive Diseases | Phase 1 | Status: COMPLETED